Laplace Interventional begins patient enrollment for tricuspid valve replacement trial
Laplace Interventional has enrolled its first three patients in the TRIUMPH pivotal trial, a study evaluating its transcatheter tricuspid valve replacement system.
Laplace Interventional confirmed the start of its TRIUMPH pivotal trial following the treatment of the first three patients at Ballad Health in Kingsport, Tennessee. The study aims to evaluate the safety and clinical efficacy of the company's transcatheter tricuspid valve replacement (TTVR) system in patients suffering from tricuspid regurgitation.
Transcatheter interventions for the tricuspid valve represent a growing focus within the cardiovascular device sector. As traditional surgical options often pose high risks for symptomatic patients, minimally invasive alternatives are increasingly sought to manage valve disease without open-heart procedures.
The trial design includes a randomized cohort intended to provide data to support future regulatory submissions. The company plans to continue site activations and patient enrollment to reach its target clinical benchmarks, which will ultimately dictate the viability of the medical device in the broader market.